CATHWORKS™

Company Overview

- **CathWorks** is a medical technology company focused on applying its advanced computational science, artificial intelligence-based platform to optimize Coronary Artery Disease (CAD) therapy decisions and elevate coronary angiography from visual assessment to an objective FFR-based decision-making tool for physicians. FFR-guided (Percutaneous Coronary Intervention) PCI decision-making is proven to provide significant clinical benefits for patients with Coronary Artery Disease and economic benefits for patients and payers. Our focus today is specifically on bringing **The CathWorks FFRangio™ System** to market to provide quick, precise, and objective intraprocedural FFR guidance that is practical for every case. The CathWorks FFRangio Solution:
  - Improves CAD and PCI decision-making
  - Reduces risks and costs associated with estimated visual assessment and invasive FFR wires
  - Makes FFR practical for every case
  - Confirms revascularization intraprocedurally
- FFRangio has received CE, FDA and Japan PMDA regulatory clearance with a broad indication for use
- **Manufacturing:** A world-class scalable global manufacturing partner in Sanmina
- **IP**: Significant IP in the physiology space
- **Employees:** ~75 full-time employees, 50 R&D and Operations focused employees in Israel, ~25 US based employees including 2 sales regions in California
- **President & CEO**: Jim Corbett – Over 35 years of experience in the medical device industry, including as CEO of Vertos Medical, Alphatec Spine, ev3, President Boston Scientific International and multiple General Management roles with Baxter (Edwards)
- **Headquarters**: Israel HQ Kfar-Saba, Israel / US HQ Aliso Viejo, CA, USA

Investment Highlights

- **Large, under-penetrated potential market opportunity estimated to be $4.0 billion+, including a $1.7bn addressable market**
  - 4 Levels of potential market including
    - Level 1: Current Invasive FFR Market (~$600+M globally)
    - Level 2: PCI – Moderate/Severe
    - Level 3: PCI – Remaining Non-Moderate/Severe
    - Level 4: Coronary Angiograms
  - ~888K Potential procedures in the US
  - 2 Rounds of independent market research in 2018 and 2019 confirmed:
    - Level 1: 85% Conversion of FFR wires in 12 months
    - Level 2: 65% Conversion within 12 months
    - Level 3: 25% Conversion within 12 months
    - Level 4: 30% Conversion within 12 months
- **Exceptional clinical and economic value proposition for patients and clinicians**
  - Large RCTs FAME and FAME 2 clinical trials (published in NEJM) already demonstrated image-based physiology significantly improves patient outcomes and reduces costs associated with patient care
  - International FAST-FFR pivotal trial confirmed high degree of accuracy of FFRangio when compared with invasive FFR wire (94% Specificity, 91% Sensitivity, 92% Diagnostic Accuracy including Best-In-Class 87% Diagnostic Accuracy in Grey Zone)
  - "FFRangio Has the promise to substantially increase physiologic coronary lesion assessment in the cath. lab, thereby potentially leading to improved patient outcomes"
  - Non-invasive technology eliminates the need for any hyperemic agent or additional invasive catheter related costs, reducing cost and risk

The CathWorks FFR$_{angio}$™ System
Real-Time Data Flow

C-Arm Imaging System



- Utilizes routine angiograms without an invasive wire, and compatible with ALL C-Arm Imaging Systems

FFR$_{angio}$ Processing Unit

- Processes images and computes objective data intraprocedurally, quickly and precisely – including multiple integration options

FFR$_{angio}$ User Interface

- Delivers comprehensive 3D physiology & FFR guidance across coronary tree – enables post innervation confirmation

Investment Highlights (Cont'd)

- **Non-invasive FFR is well positioned to replace invasive FFR**
  - High accuracy, reduced cost and elimination of risks to patients positions non-invasive FFR to quickly and effectively replace current invasive FFR alternatives
  - CathWorks product development efforts and learning from 2019 US commercial pilot has enabled FFRangio to seamlessly integrate within existing cath lab workflow
  - Significant positive experience in 2 US pilot regions

- **Strong projected financial performance**
  - Elite Gross Margin combined with significant immediate market opportunity, well positioned for fast growth
  - Elite gross margin profile of ~85% driven by differentiated product (software), compelling healthcare economics and strong value proposition to physicians, hospitals and patients
  - Positive early signs of adoption despite limited existing scale

- **Significant immediate revenue, growth and gross margin potential**
  - Product Readiness: Strong clinical data is well accepted by clinicians / Workflow integration makes adoption simple (Disposable Activation Key Card, Connectivity to PACs and C-Arm Systems)
  - Regulatory Readiness: FDA, CE and Japan PMDA approval – US Reimbursement CPT Code